4 IPOs Scheduled for the Week of March 3

Francis Gaskins  |

The full IPO calendar is available at IPOpremium.  The scheduled IPOs are ranked by IPO size.

(1) Based in Mountain View, CA, Coupons.com (COUP) scheduled a $130 million IPO on the NYSE with a market capitalization of $945 million at a price range midpoint of $13 for Friday, March 7, 2014.

COUP operates a leading digital promotion platform that connects great brands and retailers with consumers.

(2) Based in Menlo Park, CA, TriplePoint Venture Growth BDC  (TPVG) scheduled a $125 million IPO on the NYSE with a market capitalization of $129 million at a price range midpoint of $15 for Thursday, March 6, 2014.

TPVG is a business development corp (BDC) that focuses on venture growth stage companies in technology, life sciences and other high growth industries.

(3) Based in Vancouver, Canada, Aquinox Pharmaceuticals (AQXP) scheduled a $41 million IPO on the Nasdaq with a market capitalization of $107 million at a price range midpoint of $11 for Friday, March 7, 2014.

AQXP is a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation and cancer.

(4) Based in Malvern, PA, Recro Pharma (REPH) scheduled a $28 million IPO on the Nasdaq with a market capitalization of $59.2 million at a price range midpoint of $11 for Friday, March 7, 2014.

REPH is a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially in the post-operative setting.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
COUP Coupa Software Incorporated 93.82 -1.21 -1.27 829,684 Trade
REPH Recro Pharma Inc. 8.59 -0.09 -1.04 142,395 Trade
TPVG TriplePoint Venture Growth BDC Corp. 13.06 0.02 0.15 95,089 Trade
AQXP Aquinox Pharmaceuticals Inc. 2.59 -0.03 -1.15 68,311 Trade
AGTI Alternative Green Techs n/a n/a n/a 0

Comments


Watchlist

Symbol Last Price Change % Change
AAPL

     
AMZN

     
HD

     
JPM

     
IBM

     
BA

     
WMT

     
DIS

     
XOM

     

World Economic Forum at Davos 2019 - Kitty Parry CEO DeepView

Matt Bird sits down with Kitty Parry, CEO DeepView, at the World Economic Forum at Davos 2019

Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.